FINAL RESULTS OF A PHASE 1B 28-DAY STUDY OF ABI-H0731, A NOVEL CORE INHIBITOR, IN NON-CIRRHOTIC VIREMIC SUBJECTS WITH CHRONIC HBV

Conference Reports for NATAP

The Liver Meeting
San Francisco
November 2018


FINAL RESULTS OF A PHASE 1B 28-DAY STUDY OF ABI-H0731, A NOVEL CORE INHIBITOR, IN NON-CIRRHOTIC VIREMIC SUBJECTS WITH CHRONIC HBV

	Reported by Jules Levin AASLD 2018 Nov 9-13 SF